Keros Therapeutics(US:KROS) Globenewswire·2025-11-05 21:01Core Insights - Keros Therapeutics reported a significant reduction in net loss for Q3 2025, amounting to $7.3 million compared to a net loss of $53.0 million in Q3 2024, primarily due to revenue from a license agreement with Takeda Pharmaceuticals [2][10]. - The company is advancing its clinical pipeline, with plans for a Phase 3 trial of elritercept in myelodysplastic syndromes and a Phase 2 trial of KER-065 for Duchenne muscular dystrophy [2][6]. Financial Performance - Total revenue for Q3 2025 was $14.3 million, a substantial increase from $388,000 in Q3 2024, driven by $10 million in license revenue from Takeda [10]. - Research and development expenses decreased to $19.5 million in Q3 2025 from $49.2 million in Q3 2024, largely due to the transition of elritercept-related expenses to Takeda [3][10]. - General and administrative expenses rose slightly to $10.1 million in Q3 2025 from $9.8 million in Q3 2024, attributed to increased external expenses despite a reduction in compensation costs [4][10]. Cash Position - As of September 30, 2025, Keros had cash and cash equivalents of $693.5 million, up from $559.9 million at the end of 2024, which is expected to fund operations into the first half of 2028 after accounting for $375 million earmarked for stockholder returns [5][12]. Product Development - Keros is focused on developing therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family, with KER-065 aimed at neuromuscular diseases and elritercept targeting cytopenias in myelodysplastic syndromes [6][10].